Compare FHTX & ALTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHTX | ALTI |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United States | United States |
| Employees | N/A | 490 |
| Industry | Medicinal Chemicals and Botanical Products | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.9M | 492.8M |
| IPO Year | 2020 | 2021 |
| Metric | FHTX | ALTI |
|---|---|---|
| Price | $6.22 | $3.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | ★ 299.4K | 204.3K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.32 | ★ 41.11 |
| EPS | N/A | ★ N/A |
| Revenue | $30,909,000.00 | ★ $254,956,000.00 |
| Revenue This Year | $8.89 | $18.06 |
| Revenue Next Year | $20.13 | $10.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.75 | 23.21 |
| 52 Week Low | $3.27 | $2.75 |
| 52 Week High | $7.61 | $5.45 |
| Indicator | FHTX | ALTI |
|---|---|---|
| Relative Strength Index (RSI) | 51.05 | 53.69 |
| Support Level | $4.21 | $3.80 |
| Resistance Level | $6.76 | $4.75 |
| Average True Range (ATR) | 0.53 | 0.17 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 12.95 | 29.31 |
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.